Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of 14C-esketamine in Healthy Male Subjects
NCT02674295Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of esketamine in major depressive disorder (MDD) (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Characterisation and Identification of 14C-esketamine Metabolites. Started Mar 2016; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02674295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02674295.